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An observational study using pharmacy and medical claims was used to determine whether there are differences in
asthma care cost between patients that are newly started on montelukast and low-dose fluticasone propionate.
Patients were identified who had at least one ICD-9 (493.XX) claim for asthma and were newly prescribed inhaled
fluticasone propionate 44 mg (FP) or montelukast 5 or 10mg (MON). Subjects could not have had a claim for any
inhaled corticosteroid or oral leukotriene modifier in 9 months prior to the first prescription claim for either FP or
MON. They were subsequently followed for 9 months. Multi-variate regression analysis was used to determine the
influence of these single-controller therapies on post-index asthma related costs. Positively skewed cost variables
were log-transformed prior to their inclusion into the multi-variate model. Asthma-related costs were adjusted for
age, gender, health plan, co-morbidities, pre-index asthma medication use and pre-index asthma care costs. Multi-
variate regression analysis, adjusting for baseline covariates, indicated that compared to treatment with
montelukast, treatment with FP had significantly (P50?001) lower post-index total asthma related costs. Adjusted
least squares mean total asthma care costs for the 9-month post-index period were $US649 for FP 44 mg compared
to $US1028 for montelukast.
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Asthma in the United States is estimated to be responsible
for approximately 5000 fatalities, 500 000 hospitalizations
and 2 000 000 emergency department visits annually (1,2). It
has been estimated that annual costs for treating asthma,
including direct medical expenditures and indirect costs
(e.g. lost school or work days, mortality) are between
$US5?8 and $US6?2 billion (3,4). Forty-three per cent of
this total expenditure is associated with emergency room
visits, hospitalization and death (3). Another study
estimated that direct costs represented the majority of total
costs, with indirect costs only representing 12% of total
costs (4). Hospitalizations represented the single greatest
cost category, accounting for 48% of total costs in allSponsored by GlaxoSmithkline.
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0954-6111/01/030227+08 $35?00/0patients and 74% of total costs in children 4 years old. In
addition, 80% of total resources were used by 20% of the
population (4).
Successful pharmacological treatment of asthma is
dependent on a combination of effectiveness and compli-
ance with the treatment. Neither factor in isolation will
produce enhanced disease outcomes. Lack of compliance
with any medication may reduce its ecacy. However,
enhanced compliance with a less effective medicine may
achieve lower ecacy rates than lower compliance rates
with a more effective medicine. The key factor to consider
when estimating the cost-effectiveness of alternative treat-
ment regimens is the effectiveness (based on both ecacy
rates and compliance) of each drug as observed in actual
practice.
The National Heart Lung and Blood Institute (NHLBI)
and the Global Initiative for Asthma have both proposed
that patients over 12 years of age should receive inhaled
corticosteroids (ICS) as first-line treatment of mild persis-
tent asthma (5). The NHLBI guidelines proposed leuko-
triene modifiers (LTM) as an alternative controller therapy.
Since the publication of these guidelines, there have been# 2001 HARCOURT PUBLISHERS LTD
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These studies have consistently demonstrated significantly
better outcomes with ICS for all pulmonary function
parameters, including FEV1 and peak expiratory flow rates
and for the equally important patient-oriented outcomes
such as symptom scores and night-time awakening (6–8). In
addition, several studies have demonstrated that ICS reduce
hospitalization rates compared to not using ICS (9–13).
Donahue et al. observed that patients on ICS had a 50%
lower risk for asthma related hospitalizations compared to
patients on short-acting b-agonist alone (9). At present
there are no published data on the impact of LTM on
hospitalization rates. Furthermore, there is limited infor-
mation on the differences in effectiveness of ICS and LTM
under actual practice conditions.
The purpose of this study was to compare the asthma
care costs of treatment with fluticasone propionate 44mg
(FP 44), an ICS, with the asthma care costs with treatment
with montelukast 5 and 10mg, an oral LTM. This analysis
was designed to determine whether lower asthma care costs
were observed in the ‘real world’ with FP 44, as might be
predicted from the results of randomized head-to-head
trials with other low-dose ICS and LTM.
Methods
This was a retrospective administrative data analysis
utilizing medical and pharmacy claims of a multi-plan
database. The PharMetrics Integrated Outcomes1 data-
base contains medical and pharmaceutical claims from over
23 managed health plans across the United States. Of the 23
available health plans within the database, eight health
plans, with approximately 2 million patient-lives, had
sucient data to cover the enrollment and follow-up
periods used in this study; 1 April, 1997 to 30 September,
1999.
PATIENT IDENTIFICATION
Patients aged 4–64 years were included if they had an
International Classification of Diseases, 9th revision —
Clinical Modification (ICD-9-CM: 493.XX) coding for
asthma and had continuous enrollment in the health plan
for at least 18 consecutive months around the index event.
The index event was the first prescription of either inhaled
fluticasone propionate 44mg or montelukast 5 or 10mg.
During the pre-index period patients could not be receiving
any ICS or LTM. Patients had to have at least two
prescriptions for the indexed medication in the 9-month
follow-up period to be included in this analysis. In addition,
subjects were required to have been enrolled in the database
for at least 9 months prior to and 9 months following the
date of the first prescription for one of the two agents.
During the 9-month pre- and post-index periods, all
resource utilization specific to asthma (as defined by a
recorded diagnosis of asthma) and associated charges were
captured. Subjects were excluded from the analysis if they
were diagnosed at any time with cystic fibrosis (ICD=277)
or chronic obstructive pulmonary disease (ICD of 491, 492,493?2, 496). In addition, to decrease the likelihood of
including subjects with chronic obstructive lung disease,
patients who were 45 years of age or older and had more
than one prescription for ipratropium bromide during the
study period were excluded (14).
The study was conducted as an intent-to-treat analysis,
thus patients who received the alternative therapy in the
post-index period were not excluded. The base case analysis
for this study was the comparison of FP 44 mg to
montelukast 5 and 10mg. This FP strength was selected
because the lowest possible FP dose is the most clinically
relevant comparison to montelukast. In addition, clinical
studies where ICS were compared to LTM, the lowest
dose within labeling of ICS is used (6–8). Both the 5-mg and
10-mg dose of montelukast were included because 5mg is
indicated for children less than 15 years of age while
montelukast 10mg is usually reserved for patients over 15
years of age. The FP 44 mg is the lowest metered dose
inhaler strength and is indicated for all patients over 12
years of age and is used in patients aged 4–11 years.
Because, FP 110mg may be used as an alternative to FP 44
by taking fewer puffs per day, the impact of including the
110mg dose of FP was tested in a sensitivity analysis.
DESCRIPTIVE MEASURES
Asthma-related claims were tabulated over the 9-month
pre-index and post-index periods. These claims included
hospitalizations, emergency department (ED) visits, oce
and outpatient visits, ancillary and pharmacy claims related
to asthma. Total asthma charges were the sum of these
categories. For the purpose of this analysis, charges were
used in lieu of reimbursement (paid) amounts as measures
of cost. Healthcare providers, pharmacy and medical,
claims were submitted for reimbursement to each health
plan. These claims had provider charge amounts attached.
It was felt that charges were appropriate for this analysis
because reimbursement rates varied greatly between man-
aged care plans since several of the health plans were
capitated, whereas the amount charged by a provider for a
given procedure remained relatively constant across differ-
ent payer types.
A number of control variables were measured, including
patient demographic information (age, gender), co-morbid
conditions, and concomitant use of inhaled short-acting
bronchodilators, methylxanthenes, oral corticosteroids and
inhaled long-acting bronchodilators. In addition, the
number of hospital stays, the average length of a hospital
stay, and the number of claims for the index prescription
(FP or MON) was collected during the post-index period. It
was assumed that each prescription claim was for a 30-day
supply.
ANALYSIS
Pre-index characteristics were compared between treat-
ment cohorts; P-values are based on independent group
t-tests for continuous variables, independent tests of
proportions for dichotomous variables, and Wilcoxon
COST OF FLUTICASONE PROPIONATE AND MONTELUKAST IN ASTHMA 229rank sum tests for charge data (15). Univariate analyses of
changes in continuous variables consisted of Wilcoxon
signed-rank tests. Time to add alternative class of medica-
tion was compared through the comparison of survival
functions across cohorts. A generalized Wilcoxon test was
used to compare survival functions, as no assumption was
made regarding the underlying exponential model. In order
to account for differences in charge rates across geographi-
cal regions, the plan identifier was included as a covariate in
all of the multi-variate analyses, including the calculation of
adjusted means. Multiple variable linear regression analysis
was used to examine the effect of the independent variables
on the post-index log-transformed asthma-specific charges.
All cost variables were log-transformed due to the
positively skewed data (16). A multiple variable linear
regression analysis adjusting for treatment cohort differ-
ences at index was performed to determine if the differences
between cohorts in the cost of asthma-related therapy were
maintained.
Factors included in the regression analysis were patient
age, gender, health plan, pre-index asthma costs, short-
acting b-agonist use, oral corticosteroid use, salmeterol use
and theophylline use.These covariates are detailed inTable 1.
Adjusted means were generated using the same multiple
variable regression analysis on non-logged cost and are
reported as adjusted means. Non-logged cost was used to
the enhance presentation of the data to more closely mimic
‘true’ costs. Adjusted means represent the mean response
for a group averaged over the levels of all remaining
covariates in a balanced dataset. We estimated risk of
hospitalizations and ED visits with odds ratios derived
from logistic regression models adjusting for the same
factors used in the cost models. The montelukast cohort is
the referent group. All tests of significance were performed
at a=0?05. All analyses were conducted using SAS Version
7?0 (17).TABLE 1. Pre-index characteristics
FP 44mg (n=318)
Age (+SD) 25?17(+18?2)
Female (%) 57
Oral steroids* 48?43
Short-acting bronchodilators* 81?76
Methylxanthenes* 3?14
Salmeterol* 15?72
1 ED visit (%) 10?1
1 hospitalization (%) 5?0
Mean asthma charges
Pharmacy $US99?77
Emergency department $US21?05
Hospitalization $US279?12
Total asthma $US593?33
*Patients with at least one claim in the pre-index period (%).
FP: fluticasone propionate; ED: emergency department.SENSITIVITY ANALYSIS
Sensitivity analyses were performed on several subsets of
the data. First, the treatment cohorts were divided into ages
4–11 years and 12–64 years, and comparisons on total
asthma care costs were performed. Second, patients
identified as using FP 110 mg were also included in the
analysis. The effect on total asthma care costs in this larger
FP cohort was compared to the montelukast cohort.
Results
A total of 318 new users of FP 44 and 575 new users of
montelukast met the inclusion/exclusion criteria. Pre-index
characteristics are presented in Table 1. The gender
distribution was similar, although the FP 44 patients were
significantly younger (P=0?023). There were no significant
differences in co-morbidities between groups. During the
pre-index period, significantly more (P50?04) short-acting
b-agonist, salmeterol and oral steroids were dispensed to
FP 44 users compared to patients dispensed montelukast.
Montelukast patients had significantly more prescription
claims for theophylline and other methylxanthenes during
the pre-index period compared with FP 44 patients
(P=0?018).
Montelukast patients received, on average, 4?6 prescrip-
tion claims for montelukast during the treatment period,
while patients on FP 44 averaged 3?4 FP prescription claims
during the same period, (P50?001). The number of patients
receiving a short-acting b-agonist was reduced from 81?8%
to 78% (4?8% reduction) for patients dispensed FP 44, and
reduced from 69?9% to 66?1% (5?4% reduction) for
patients dispensed montelukast. The use of oral corticos-
teroids declined in the post-index period for users of FP and
montelukast, however there were no significant differencesMontelukast 5 and 10mg
(n=575)
P-value
28?06(+18?1) 0?023
58 NS
38?26 0?003
69?9 0?001
6?96 0?018
10?96 0?040
8?4 0?390
3?8 0?393
$US97?96 NS
$US16?47 NS
$US225?24 NS
$US500?23 NS
TABLE 2. Mean unadjusted pre- and post-index asthma-related charges
Pre-index ($US) Post-index ($US) Difference ($US) Change (%) P-value*
FP 44mg (n=318)
ED 21?05 7?61 713?43 763?8 0?0014
Inpatient 279?12 154?54 7124?58 744?6 0?0287
Ancillary 27?17 12?11 715?07 755?5 0?3684
Pharmacy 99?77 328?51 228?73 229?3 0?0001
Outpatient 166?22 167?84 1?62 0?97 0?9856
Total cost 593?33 670?61 77?27 13?0 0?0001
Montelukast 5 and 10mg (n=575)
ED 16?47 10?30 76?17 737?5 0?0519
Inpatient 225?24 277?25 52?01 23?1 0?9910
Ancillary 6?81 9?83 3?01 44?2 0?5563
Pharmacy 97?96 512?34 414?38 423?0 0?0001
Outpatient 153?74 159?10 5?36 3?5 0?8076
Total cost 500?23 968?82 468?59 93?7 0?0001
*Wilcoxon sign-rank test.
FP: fluticasone propionate; ED: emergency department.
FIG. 1. Percent remaining of index treatment. Significantly more patients treated with MON 5 and 10mg (- - -)
received an ICS or another LTM compared to FP 44 mg (—) who received an LTM or another ICS. Patients remained
on FP 44 mg alone for a significantly longer period of time compared to MON. *P50?001 FP vs. MON. FP: fluticasone
propionate; MON: montelukast; LTM: leukotriene modifier; ICS: inhaled corticosteroid.
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post-index period. In addition, 17?3% of the FP 44 patients
were dispensed either a LTM or an ICS other than FP,
while 38?1% of the montelukast patients were dispensed
either an ICS or a LTM other than montelukast
(P50?001). The mean time to add these medicationsamong montelukast patients was 123?3+130?3 days
compared to 157?5+144?2 days among the FP 44 mg
patients. Comparison of time-to-add survival curves illu-
strated that montelukast patients were more likely to
receive additional controller treatment sooner than FP
patients (P5 0?0001; Fig. 1).
TABLE 3. Parameter estimates of post-index logged asthma-specific charges*
Variable Mean Standard deviation b-coecient Standard error P-value
Intercept 6?1502 0?1020 0?0001
FP 44mg 0?3561 0?4791 70?4583 0?0610 0?0001
Pre-index logged asthma costs 4?7970 2?2078 0?0366 0?0134 0?0065
Age 27?0302 18?1715 0?0001 0?0017 0?9487
Gender 0?4233 0?4944 70?0131 0?0577 0?8200
Pre-index b-agonist use 0?7413 0?4382 0?0421 0?0668 0?5282
Pre-index oral steroid use 0?4188 0?4936 0?0969 0?0585 0?0982
Pre-index theophylline use 0?0560 0?2300 0?0780 0?1243 0?5304
Pre-index salmeterol use 0?1265 0?3326 0?2783 0?0846 0?0010
Health plan{ 0?0056 0?0747 70?1670 0?3733 0?6547
0?0202 0?1406 70?2453 0?1981 0?2159
0?0594 0?2364 0?0255 0?1187 0?8299
0?1008 0?3012 0?2336 0?0950 0?0141
0?1702 0?3760 0?1610 0?0778 0?0388
0?0056 0?0747 0?4043 0?3730 0?2787
Adjusted R2=0?0808.
*Base case FP 44 mg vs. montelukast 5 and 10mg.
{Data from seven health plans; two small plans were collapsed into one group.
FP: fluticasone propionate.
FIG. 2. Adjusted mean asthma care charges in the 9-month
post-index period. Least-squares mean of asthma specific
costs adjusting for differences in gender, age , plan, pre-
index b-agonist, salmeterol, oral corticosteroid and
theophylline use, and pre-index total asthma charges
observed in the pre-index period. FP 44 mg is associated
with lower overall asthma care costs compared to MON.
*P50?001 FP vs. MON. FP: fluticasone propionate;
MON: montelukast.
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uncommon in the pre-index period: the number of FP 44
patients with at least one asthma-related hospitalization
was 16 (5%) and 22 (3?8%) for montelukast patients. These
were reduced to 4 (1?3%), a 75% reduction from the pre-
index period for FP 44 and 15 (2?6%), a 32% reduction
from the pre-index period for patients on montelukast. FP
44 was associated with a non-significant (60%) lower risk
for an asthma-related hospitalization compared to mon-
telukast (adjusted OR 0?4, P=0?153) in the post-indexperiod. For patients with a hospital stay, the length of stay
was longer in the post-index period compared to the pre-
index period for both groups. For patients who were
hospitalized, FP 44 patients were in the hospital for 1?1
days in the pre-index period and 2?1 days in the post-index
period, while patients on montelukast were in the hospital
for 1?8 days in the pre-index period and 2?8 days in the
post-index period. ED visits were reduced from 10% to
4?7% (53% reduction) for FP 44 and were reduced from
8?3% to 5?4% (35% reduction) for patients on montelu-
kast. No significant differences were observed in the
number of ED visits in the post-index period between
treatment groups (adjusted OR). The mean pharmacy, ED,
hospitalization, outpatient and ancillary charges before and
after the introduction of either FP 44 or montelukast are
shown in Table 2.
Results of the base case multiple variable regression
analysis is reported in Table 3. These results showed that
after adjustment for the differences observed in the
populations, FP 44 was associated with 46% lower asthma
care costs compared to montelukast during the 9-month
post-index period. Adjusted mean total asthma care charges
were $US694?04 in the 9-month post-index period for FP
44mg compared to $US1027?71 for montelukast (Fig. 1).
A sensitivity analysis was performed comparing total
asthma care charges between FP 44 and montelukast 5 and
10mg for ages 4–11 years and for ages 12–64 years. In
addition, patients initiated FP 110mg were included in the
overall comparison with montelukast in order to compare
total asthma care charges.
Comparisons were made between groups using the same
multiple variable regression analysis technique. Patients
treated with FP had significantly lower asthma care costs
TABLE 4. Sensitivity analysis: total unadjusted and least squares mean of post-index asthma-specific costs
Unadjusted ($US) Adjusted*{ ($US) Unadjusted ($US) Adjusted*{ ($US)
FP 44mg (n=318) 670?61 694?04 MON{ (n=575) 968?82 1027?71
FP 44 and 110 mg
(n=901)
857?59 883?58 MON{ (n=575) 968?82 1053?98
FP 44mg (4–11 years)
(n=111)
773?64 557?09 MON{ (4–11 years)
(n=153)
1109?67 1018?78
FP 44mg (12–64 years)
(n=207)
615?36 707?95 MON{ (12–64 years)
(n=422)
917?75 1045?95
*P50?0001 FP vs. MON.
{Least-square means of asthma specific costs, adjusting for the effects of gender, age, pre-index asthma medication use, pre-
index total charges, and plan.
{5 and 10mg. Doses of FP: fluticasone propionate; MON: montelukast.
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lower costs for patients aged 4–11 years, 50% lower costs
for patients aged 12–64 years, and 32% lower costs for FP
44 and 110 mg compared to montelukast (P50?0001). This
sensitivity analysis shows that FP is consistently associated
with total lower asthma care charges in the various
subgroups and dosage strengths compared to montelukast.
Unadjusted and adjusted means for each group are shown
in Table 4.
Discussion
Inhaled corticosteroids have been shown in recent studies to
lower the overall morbidity of asthma by reducing the risk
of a hospitalization. Donahue et al. retrospectively assessed
the relative risk of hospitalization for patients according to
short-acting b-agonist use and ICS use. After adjusting for
the use of short-acting b-agonists, the use of inhaled
steroids was associated with a 50% decrease in the risk of
hospitalization relative to persons who were not dispensed
ICS (9).
Another retrospective study concluded that an increase in
drug expenditures and the increase in the use of ICS were
associated with a 31 per 1000 reduction in ED visits and a
35 per 1000 reduction in asthma-related hospitalization
(11). The authors concluded that the savings from these
service changes helped to offset the increase in drug
spending. In this study the use of FP 44 was associated
with a non-significant 60% lower risk for an asthma related
hospitalization compared to montelukast. In addition, FP
44 had an estimated 37?7 per 1000 reduction in asthma
related hospitalizations compared to a 12?2 per 1000
reduction for montelukast. The asthma related events
observed in the treatment period had an increase in the
length of a hospital stay of about 1 day for both cohorts.
This observation was unexpected but may be associated
with the greater reduction for hospitalizations in the less
severe inpatient events.
Leukotriene modifiers have been in use for the treatment
of asthma in the United States since 1997, however, no
evidence has yet been presented that demonstrates theability of LTM to reduce asthma hospitalizations and
emergency department visits as demonstrated with ICS. In
addition, recent studies have demonstrated that treatment
of persistent asthma with ICS results in better symptom
control and superior lung function, compared to the use of
leukotriene-modifying agents (6–8). To date, no study has
evaluated the cost implications of each treatment. Compar-
ison of the economic value of ICS to oral LTM agents in
the treatment of patients with mild, persistent asthma is of
great importance, as the results of economic analyses of
pharmaceuticals are often used by policy-makers in making
treatment and prescription decisions.
The present investigation was based on data from actual
practice conditions. While the results from clinical trials
have high levels of internal validity, their generalizability to
the clinical practice setting is often questionable. The
clinical trials are performed under ideal settings and do not
take into account patient variables such as the differences in
the compliance level between different therapy regimens.
The possible role of non-compliance on the outcome of
asthma therapy is best explored using data from a ‘real
world’ setting.
In this study, patients initiated FP 44 had lower overall
asthma related costs, fewer hospitalizations, less need for
additional controller medications, and longer maintenance
on their initial therapy compared with patients initiated
montelukast. All of these parameters may be viewed as
proxy measures of ecacy. This data indicates that FP 44
provides superior asthma control compared to montelu-
kast, a LTM, in the ‘real world’ and supports the
conclusions of a recent clinical trial demonstrating the
advantages of inhaled corticosteroids as compared to
montelukast (6). In addition, it is important to note that
the greater reductions in ED and hospitalization charges
seen in FP 44 patients occurred despite the lower number of
mean prescription claims for FP 44 compared to montelu-
kast.
The number of prescription claims may not be a very
reliable indicator of patient adherence, since, depending on
health plan, patients may get more than a 30-day supply of
medication for each prescription claim. However, in this
analysis prescription claims were used only as a relative
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the adherence of FP metered dose inhalers since phy-
sicians may prescribe these outside of approved dosing,
such as two puffs once daily or one puff twice daily instead
of the labeled dose of two puffs twice daily (18). Presently,
studies that show differences in refill rates or adherence
between two treatment groups without showing how
that relates to overall costs or effectiveness may be
misleading.
It has been reported that 30% of fatal asthma occurs in
patients previously thought to have mild asthma (19). In
addition, a recent study by Suissa et al. concluded that
regular users of low-dose ICS decrease their risk of an
asthma-related death by 21% with each additional canister
of ICS used in a year (20). Such benefits still need to be
demonstrated with the use of LTM. It is therefore
important that patients with mild asthma be treated with
an ICS in order to provide protection against serious
adverse events, including death.
Limitations of this study must be recognized. The study
compared two treatments over a 9-month period. There-
fore, the observed differentials in resource utilization
cannot be easily extrapolated beyond the 9 months
following the initiation of therapy. Secondly, the adminis-
trative data used for the analysis was claims data from a
managed care population, and thus, the findings may not be
able to be extrapolated to other populations or settings. In
addition, the small sample size and relative rareness of
hospitalizations may also explain why a statistically
significant difference was not observed in hospitalization
rates in this study even though the odds ratio was less
than 0?5.
Another limitation of claims analysis is the diculty in
identifying comparable treatment groups since the cohorts
were not randomized. This limits the internal validity of the
study. Comparison of raw data between the two cohorts is
of limited value in detecting associations between therapy
and post-index cost of care. Univariate analyses performed
on unadjusted means do not take into account differences
in disease or population characteristics between the two
cohorts. It could be argued that any observed differences in
asthma-specific costs are the results of confounding
variables because of disease or population characteristics
which differ between the two cohorts. Confounding
variables cannot be easily controlled in the design of an
observational study, but can be minimized through proper
analysis. Differences observed in the pre-index character-
istics of these two cohorts is a common occurrence in
retrospective data analyses. The usual method for account-
ing for this lack of balance is to conduct a multivariate
regression analysis which is a method that estimates the
association between the intervention and outcome as well as
other variables that may confound or modify the effect of
the treatment. The adjusted means are a way to present the
results of such regression analysis. The adjusted means
correspond to the expected or predicted mean values that
are derived using the regression model assuming that the
disease and population characteristics are the same in both
treatment populations. As illustrated in the current
analysis, fluticasone propionate therapy was associatedwith lower treatment costs even after the effects of other
variables from the pre-index or baseline period (such as age
and pre-index costs) were taken into account. This
association was consistently observed in the analysis of
subjects that received FP 44 or 110mg, in subjects aged 4–11
years and in subjects aged 12–64 years. This sensitivity
analysis supports the robustness of the base–case findings.
Randomized clinical trials have well defined populations
that are matched at baseline. Selection criteria are very
restrictive which eliminates patients with either more
mild or severe disease. Retrospective claims analysis is
more inclusive but treatment cohorts have greater baseline
variability. The consistent results favoring fluticasone
noted in these two distinct forms of analysis confirms
the findings of each and increases the generalizability of
the outcomes.
The analysis classified patients according to initial
assignment regardless of subsequent switches or augmenta-
tions. This intent-to-treat design focuses on all conse-
quences of initial treatment selection and regards switches
or augmentations as common and important consequences
of initial treatment selection. The extent of switching or
augmentation with another controller medication may be a
proxy for asthma control. Excluding the outcomes of those
patients whose therapy was augmented would have biased
the results because only the healthiest subjects would have
remained for both groups. In this study significantly more
patients treated with montelukast switched or augmented
their therapy with another LTM or ICS compared to
patients treated with FP 44 mg.
As the cost of healthcare continues to rise and as the
payers of healthcare become more involved in medical
decisions, the need for outcomes data in documenting what
works in patient care is imperative. Outcome analysis
should lead to better use of resources with a goal of helping
to reduce costs (21). As the current study illustrates, the
initiation of therapy with fluticasone is associated with
lower asthma-related medical costs compared to the
initiation of montelukast treatment over a 9-month period
and after adjusting for confounding variables of age, co-
morbid condition and concomitant medication. The poten-
tial cost savings pursuant to fluticasone therapy compared
to montelukast should be considered as a potential outcome
of interest along with clinical outcomes when selecting the
best prophylactic therapy for the treatment of persistent
asthma.
This study confirms the conclusion of the National
and International Asthma Guidelines, which recommend
the use of ICS as the first-line controller therapy for
asthma (5). This study shows that there are better clinical
outcomes and lower utilization of resources with FP 44
compared to montelukast despite a greater number of refills
observed with montelukast. This analysis, which utilized
commercial claims data, arms the results of RCTs, which
demonstrate the greater ecacy of FP relative to LTM. The
cost savings associated with lower resource utilization,
combined with the lower cost of concomitant medications
seen in FP 44 patients, supports the use of FP 44 over
montelukast 5 and 10mg as a first-line controller medica-
tion for asthma.
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